Cattle and Sheep Vaccine Market Report

Cattle and sheep vaccines are used to prevent the animals from diseases such as Foot and mouth disease (FMD), Bluetongue virus, Lumpy Skin Disease (LMD), Trichomoniasis, Brucellosis, etc. The FMD is a severe, highly transmissible disease in cattle and sheep that has a significant economic impact. These economic impacts not only cause losses in animal productivity but can also drive up the cost of both treatment and vaccination programs. In 2024, a team of Indian scientists made significant progress in understanding the genetic makeup of the virus responsible for lumpy skin disease that led to the deaths of approximately 1 million cattle since May 2022. Advancements in biotechnology and new vaccine technologies make cattle and sheep vaccines more effective. Improved vaccine formulation, adjuvant, and delivery methods result in an improvement of vaccine efficacy. This aligns with the cattle and sheep vaccine market analysis and supports the expansion of the cattle and sheep vaccine market size.

Cattle and sheep are the major sources of primary as well as secondary food products used by humans in their day-to-day life, supported by quality cattle feed supply systems. As a result, ensuring the health of cattle and sheep has become a top priority, encouraging farmers to adopt advanced practices for long-term health and productivity. The competitive conflict is expected to rise, as companies continue to introduce advanced vaccines and expand their distribution network to tap into new streams. Concerns about food security are growing because of variations in food choices brought on by changing lifestyles; as a result, the need for cattle and sheep vaccines is increasing. These elements bring more opportunities for companies to come up with advancements for market expansion. These developments shape the cattle and sheep vaccine market trends and improve the overall cattle and sheep vaccine market outlook, while influencing cattle and sheep vaccine market segmentation and driving cattle and sheep vaccine market growth, affecting cattle and sheep vaccine market share among key players.

According to NCBI (National Centre of Biotechnology Information), the mortality rate is 5% in adult animals and the morbidity rate of FMD reaches up to 100%. Hence, this is the cause for serious production losses expressed in low milk production and weight loss due to loss of appetite. The growing demand for animal protein, expansion of livestock production and rising awareness of preventive healthcare and advancements in animal nutrition bring opportunities for the cattle and sheep vaccines market. The high demand for bovine vaccines is driven by the need to protect cattle and sheep from life-threatening diseases and to maintain the health of this significant livestock population. The increased adoption of cattle and sheep vaccination programs drives the growth of the cattle and sheep vaccine market.

New vaccine manufacturing methods have evolved because of developments in technology and medicine, broad knowledge of immunology, biochemistry, molecular biology, among other basic science disciplines, alongside livestock management tools such as sheep hair cutting machines. This may help vaccine manufacturers to understand the disease and develop new adjuvants for the prevention of diseases. Genetic engineering, proteomics, and other technologies have aided in implementing novel vaccine theories, resulting in the discovery of new cattle and sheep vaccines and the improvement of the existing ones. The next generation of vaccines, such as subunit vaccines, DNA vaccines, recombinant vaccines, and vector vaccines, is increasingly gaining scientific and public attention and is being seen as a viable replacement for conventional vaccines. Another opportunity to drive cattle and sheep market growth is a collaboration between vaccine manufacturers and research institutes for the development of innovative vaccines. These developments reflect the broader cattle and sheep vaccine industry analysis.

• The Demand for animal protein is projected to continue to grow.
• Sustainable livestock production practices aim to meet the needs of rising animals for food while minimizing negative environmental impacts.
• Awareness of preventive healthcare grows economies and improve health of cattle and sheep.
• Significant advancement in traditional vaccines such as recombinant, vector and irradiated vaccines.

The rise of Lumpy skin disease in cattle is the main reason behind the slower growth of milk production. Animal disease threatens the lives of millions of livestock on a daily basis. Stringent regulations related to vaccine approvals, animal welfare, and limited awareness about the benefits of vaccination among cattle and sheep farmers in some regions is a major restraint for market growth. The other restraint is a complex approval process and extensive testing requirements, which pose a challenge for vaccine manufacturers, leading to delays in product launches. The Animal and Plant Health Inspection Service’s Centre for Veterinary Board (CVB) oversees the regulation of veterinary vaccinations in the United States. Animal health companies are granted product and establishment licences by CVB in order to produce and market veterinary biologics, which may contribute to the growth of cattle and sheep vaccines. Manufacturers can capitalize on the growing demand for advanced vaccines to address evolving threats.

As per NCBI in Nov 2023, in dairy farms with a high percentage of infected cows (more than 20%), the economic loss was estimated at US$ 5500. Such economic losses may hamper the growth of the market. Use of vaccination methods and technological platforms for cattle and sheep may provide some useful insights. Adoption of vaccination is the only way for healthy cattle and sheep; due to vaccination, many diseases can be cured, but the cattle and sheep vaccine market is likely to be hampered by the lack of adoption of vaccination by smallholder farmers. For instance, to increase vaccine adoption rates, smallholder farmer education and outreach efforts are needed.

Continuous R&D investments and initiatives by key players are driving the market growth. For example, in 2024, Boehringer Ingelheim (BI) Pharmaceuticals, Inc had launched its adjuvanted first bluetongue virus serotype-3 vaccine. BI, in partnership with Bioveta, a veterinary manufacturer with a concentration on vaccinations, developed the vaccination, and it was intended to be made available in Bluetongue Virus (BTV)-3 affected countries beginning May 2024. LSU (Louisiana State University) researchers had developed a new cost-effective vaccine for Bovine Respiratory Disease (BRD) and related illness. This vaccination would prevent cattle and sheep from clinical signs and mortality. The presence of key players such as Virbac, Pfizer INC., and Bayer AG is expected to drive market growth. Similarly, the government’s growing initiatives to promote vaccination for cattle and livestock in the Asia Pacific are expected to make more profits. Government support, regulatory frameworks, and public-private partnerships play a critical role in vaccine development, efficacy & distribution to cattle and sheep vaccine producers worldwide. Global core cattle vaccine manufacturers include Merck Animal Health, Zoetis, etc. These top 2 companies hold a large share. 

On the basis of geography, the cattle and sheep vaccine market is classified into North America, Europe, Asia-Pacific, and the rest of the world. North America is forecasted to drive demand for cattle vaccines in the market. Continuous R&D investments by key players and the rapid adoption of efficient vaccines are expected to advance the market growth of North America. Due to the development and standardization of diagnostic tests, Latin America is expected to witness remarkable growth during the forecast period. Vaccine development is advancing at an accelerated pace in North America, which has advanced biotechnology and pharmaceutical industries, while focusing on manufacturing useful vaccines. To prevent cattle from the disease, vaccination programmes have become more popular, according to the cattle and sheep vaccine market forecast.

According to NCBI (National Centre for Biotechnology Information), the disease is estimated to circulate by 77% of the global livestock population, and the incurred cost in Africa is 50% of the total cost of the continent. As per the FMD vaccine project in Eastern Africa, the highly contagious viral disease affects 77% of cattle, sheep, and other cloven-hoofed ruminants as well. There was an FMD outbreak in Indonesia in May 2022. Currently, it is present in Asia, the Middle East, Africa, and parts of South America.

Geographic Coverage of the Report:

• Market segmentation across livestock prophylaxis, serology, and herd immunization pipelines is assessed alongside demand shifts in endemic disease zones, with the cattle and sheep vaccine market reflecting structural linkage to broader animal health ecosystems and parent market evolution; cattle and sheep vaccine market consumption patterns vary by husbandry scale.
• Market dynamics (DROT) interplay with regulatory tightening and zoonotic risk monitoring shapes investment direction, while pricing analysis and sales & distribution strategies influence uptake across rural veterinary channels; the cattle and sheep vaccine market is further defined by long-term market size & forecast metrics and the cattle and sheep vaccine market.
• Supply chain & value chain mapping from antigen production to cold-chain logistics highlights bottlenecks in rural last-mile delivery, while latest developments & innovations in multivalent formulations reshape herd immunity approaches; regulatory landscape variations across regions directly affect commercialization speed in the cattle and sheep vaccine market.
• Competitive analysis spanning multinational animal health portfolios and regional vaccine producers reveals shifting market share by companies, while regional market insights and country-level forecast for the next decade highlight uneven adoption curves; strategic positioning in the cattle and sheep vaccine market increasingly depends on localized immunization programs and distribution depth.
• Mergers & acquisitions activity among veterinary biologics firms accelerates portfolio consolidation, supported by demand analysis across high-burden livestock regions and evolving pricing structures; investor positioning in the cattle and sheep vaccine market reflects resilience-driven expansion strategies aligned with preventive animal healthcare adoption.